Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Estrogen receptor (ER), progesterone receptor (PR), and HER2/neu are the most important tissue markers in the management of breast cancer, in the adjuvant setting and in the setting of metastatic disease. Many studies have demonstrated a discordance of expression between primary breast cancer, synchronous axillary metastases, and metastatic sites. The aim of this article is to review studies on discordance of expression of these predictive parameters to better understand the importance of a reassessment of biomolecular status to modify treatment strategies. We performed a literature review to identify studies that assessed ER, PR, and HER2 discordance between primary breast cancer, synchronous axillary lymph node metastasis, and other metastatic sites. We reviewed these data related to (1) relevance of discordance rates in clinical practice and (2) therapeutic consequences of discordance rate. Results were analyzed qualitatively. Changes in ER and particularly in PR are observed in locoregional and in distant metastases reaching a rate of 10% to 30% for ER and 20% to 50% for PR. The loss of PR is more frequent than ER loss. High HER2 concordance between primary tumors and axillary lymph node or distant metastases has been demonstrated in many studies; in the discordant cases, it is more frequent to have HER2-positive metastases with negative primary tumors than the opposite. A reassessment of biomolecular status in residual tumors after neoadjuvant treatment or in metastatic sites is advisable, whenever it is possible, to correct/modify the treatment schedule and to estimate the actual prognosis.
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy. Electronic address: sbrn.rossi85@gmail.com.
Sabrina
S
Rossi
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Michele
M
Basso
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Antonia
A
Strippoli
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Vincenzo
V
Dadduzio
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Eleonora
E
Cerchiaro
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Rosalba
R
Barile
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Ettore
E
D'Argento
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Alessandra
A
Cassano
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Giovanni
G
Schinzari
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
Carlo
C
Barone
D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008198:Lymph Nodes / Q000378:metabolism; D008207:Lymphatic Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
Biomolecular status; Discordance; Lymph nodes; Metastatic disease; Target therapy